CANCER CARE ONTARIO

Meeting of the Board of Directors
Tuesday, October 18, 2016
11:30 a.m. – 12:00 p.m.
620 University Avenue, Toronto, 16th floor Boardroom and via Teleconference

MINUTES OF THE PUBLIC SESSION

Members Present By Teleconference: Ratan Ralliaram (Chair)
Bonnie Adamson
Scott Campbell
Dr. Euan Carlisle
Malcolm Heins
Shoba Khetrapal
Patricia Lang
David Ross
Harvey Thomson
David Williams

Management and Other CCO Staff Present:
Mr. Michael Sherar (President & CEO)
Ms. Elizabeth Carson
Mr. Jason Garay
Mr. Garth Matheson
Dr. Robin McLeod
Dr. Linda Rabeneck
Mr. Elham Roushani
Ms. Rebecca Harvey
Ms. Paula Knight
Ms. Naeema Tharani (recorder)
Ms. Sandra Hua
Mr. Jackson Wood
Ms. Christine Gan
Mr. Alwin Kong
Ms. Nadia Jandali Chao

1. CHAIR’S REMARKS

1.1 Call to Order

Mr. Ralliaram called the meeting to order at 11:32 a.m.

1.2 Disclosure of Conflicts of Interest

Mr. Ralliaram asked Board members to declare any conflicts of interest. None were declared.

1.3 Chair’s Introduction

The Annual Business Plan (ABP) has been reviewed by the Audit and Finance and Strategic Planning, Performance and Risk Management committees independently and approved during the joint Audit and Finance and Strategic Planning, Performance and Risk Management committee meeting on October 6, 2016. The ABP is now coming to the Board of Directors for approval. Elham will lead a review of the ABP, highlighting any changes made since the October 6 meeting, as well as share any discussions that have taken place with the MOHLTC.
Elham led a review of the changes made to the ABP since the October 6 meeting and shared the highlights of discussions that have since taken place with the MOHLTC. The following is a summary of the discussions:

- **Page 15:** A discussion took place during the October 6 meeting, explaining how the funding works. These details are included on pages 15 and 16.

- **Page 19:** No change has been applied yet. However, since the October 6 meeting, the MOHLTC has asked that we change the timing of FIT Kit Implementation. The legislative changes required to support the initiative will not be made in 17/18 and as a result, we will be pushing the request to the next fiscal year (2018/19). The amendment to the ABP will be made after this meeting and it is requested that approval of the ABP be provisional of this amendment.

- **Page 24:** A table has been included to show the increase in cancer incremental volume dollars (4.8%) as a result of a discussion that took place during the October 6 meeting. The revisions have also been applied to the ABP (pages 68 and 69).

- **Page 31:** A minor change may be made to the Ocular Brachytherapy ask. The MOHLTC may decide to fund the program from case 0 as opposed to number of cases completed. As a result of the change, there might be a minor increase in the ask.

- **Member question:** Has the MOHLTC accepted the plan?
  **Mr. Roushani response:** Yes. The ADMs try to align our plan to the funding they will be providing us and therefore the ABP is reflective of what the MOHLTC wishes to fund us for.

- **Member question:** What are the implications for delaying the FIT Kit Implementation program?
  **Dr. Rabeneck response:** There is minor impact to the timelines. The plan was to launch the FIT Kit by the 3rd or 4th quarter of 2017/18. As a result, the funds would not be required until April (beginning of Q1 of 2018/19). A description of the ask will still be included in the 2017-20 ABP.

- **Member question:** If the MOHLTC only allowed CCO to include 2 or 3 asks in the ABP, what would we do?
  **Mr. Sherar response:** The vast majority for increase in funding is for volumes. This year, we worked together with the MOHLTC to ensure the ABP asks are aligned with the MOHLTC commitments for next year (2017/18). There is no indication that the volumes are at risk of not being funded, but if the MOHLTC was to come back to us, we would look to our capacity to prioritize. Possible mechanisms for addressing limited volume funding include paying less (rates) but expect the same volumes, and not paying for additional volumes. The process for identifying ways of addressing the issue would be reviewed with hospitals.
  **Member comment:** A large portion of the volumes ask is for stem cells, and these volumes have already been committed by MOHLTC.

_Note: Page numbers referenced are the page numbers of the meeting package (top right corner), not the individual documents (bottom right corner)._
Mover: Malcolm Heins; Seconder: Shoba Khetrapal

3 TERMINATION OF PUBLIC SESSION

The public session of the Board meeting terminated at 11:47 a.m.

Date and Location of Upcoming CCO Board Meeting: December 8, 2016: 525 University Avenue